Welcome to our dedicated page for Belite Bio SEC filings (Ticker: BLTE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Belite Bio, Inc. filings document foreign-issuer disclosures for a clinical-stage biopharmaceutical company developing tinlarebant for degenerative retinal diseases. Form 6-K reports furnish press releases on clinical-trial progress, FDA-related regulatory updates, financial results, annual-report availability, material agreements, shareholder matters, and capital-structure activity involving American Depositary Shares.
The company's Form 20-F reporting framework covers audited consolidated financial statements and public-company disclosure for BLTE as a foreign private issuer. Its filing record centers on STGD1, geographic atrophy in advanced dry AMD, tinlarebant development, financing activity, governance matters, and the incorporation of furnished reports into effective Securities Act registration statements.
Belite Bio Chief Medical Officer-linked entity sells ADSs. Bioptima Ltd., an entity associated with Chief Medical Officer Hendrik Peter Scholl, reported open-market sales totaling 10,000 American depositary shares of Belite Bio on June 18, 2026. The trades were executed in multiple blocks at prices ranging from about $143.90 to $147.11 per ADS, with some prices disclosed as weighted averages across narrower intraday ranges. Following these transactions, Bioptima Ltd. indirectly holds 24,904 American depositary shares of Belite Bio.
Dr. Hendrick P. Scholl reported a disposition notice under Rule 144 describing a sale of 10,000 American Depositary Shares on 06/16/2026. The filing lists vested RSUs of 2,500 ADS (vested 10/17/2025) and 7,500 ADS (vested 11/03/2025) as compensation-related securities. The Form 144 was filed in connection with ADS trading on NASDAQ.
Belite Bio’s Chief Medical Officer, through affiliated entity Bioptima Ltd., reported net open-market sales of 10,000 American depositary shares (ADS) of BLTE on June 16. Each ADS represents one ordinary share. The sales occurred in multiple trades at prices ranging roughly from $137.19 to $145.60, based on weighted-average price disclosures. After these transactions, indirect holdings reported by Bioptima Ltd. stand at 32,946 ADS, indicating the CMO remains a significant indirect holder.
BLTE submitted a notice under Rule 144 proposing the sale of 10,000 American Depositary Shares (each representing one ordinary share). The shares are described as Vested RSUs with a vesting date of 10/17/2025. The filing date shown is 06/16/2026.
Belite Bio has completed its rolling New Drug Application submission to the U.S. FDA for tinlarebant, an investigational once-daily oral therapy for Stargardt disease type 1 (STGD1). STGD1 is a rare inherited retinal disease affecting an estimated 53,000 people in the U.S. with no approved treatments.
The NDA was submitted under Breakthrough Therapy Designation, reflecting the high unmet medical need. The FDA will conduct a 60-day review of the completed application, after which, if accepted, a PDUFA target action date will be assigned. Tinlarebant previously met the primary endpoint in the Phase 3 DRAGON trial by significantly reducing the growth rate of retinal lesions versus placebo.
Tinlarebant has multiple regulatory designations in the U.S., Europe, Japan, and Switzerland for STGD1, and is also being evaluated in trials for geographic atrophy in advanced dry age-related macular degeneration.
Belite Bio reported a larger first quarter 2026 loss while moving its lead eye drug toward potential approval. The company has initiated a rolling New Drug Application submission to the FDA for tinlarebant in Stargardt disease type 1, with completion expected in the second quarter of 2026.
Belite held $276.4 million in cash and cash equivalents and $522.2 million in U.S. treasury bills and notes as of March 31, 2026. Higher spending on clinical trials, manufacturing and commercialization buildup drove research and development expenses to $15.7 million and selling, general and administrative expenses to $17.0 million.
GAAP net loss widened to $26.9 million from $14.3 million a year earlier, while non-GAAP net loss, excluding share-based compensation, increased to $13.7 million from $7.6 million, reflecting heavier investment ahead of potential commercialization.
Belite Bio, Inc. reports a beneficial ownership statement for Yu-Hsin Lin. The filing shows 1,253,935 Ordinary Shares beneficially owned by Mr. Lin, equal to 3.1% of the class. The filing states the company had 40,085,091 Ordinary Shares outstanding as of March 31, 2026.
The notes state Mr. Lin is deemed to hold a total of 2,728,462 Ordinary Shares when including (i) 353,083 shares directly held, (ii) 900,852 shares underlying vested or soon-to-vest options and RSUs, and (iii) 1,474,527 shares held indirectly through Lin BioScience, Inc. Mr. Lin disclaims investment and disposition power over the indirect holdings.
Belite Bio Chief Scientific Officer Nathan L. Mata sold shares of the company in pre-planned trades. On May 7, 2026, he executed four open-market sales totaling 666 American depositary shares at prices ranging from about $152 to $155 per share.
Each American depositary share represents one ordinary share of Belite Bio. The sales were made under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-scheduled. Following these transactions, Mata reported no American depositary shares held directly and no remaining derivative positions in this filing.
Belite Bio Chief Scientific Officer Nathan L. Mata reported selling a total of 1,000 American depositary shares (ADS) of BELITE BIO, INC in multiple open-market transactions. The sales occurred on May 6, 2026 at prices ranging from about $151.57 to $156.00 per ADS. Each ADS represents one ordinary share of the company. The filing notes that these transactions were made under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-arranged rather than timed discretionarily.
Belite Bio, Inc. Chief Scientific Officer Nathan L. Mata reported open-market sales of 1,000 American depositary shares (ADSs) on May 5, 2026. The ADSs were sold in multiple trades at prices ranging from about $153.92 to $158.11.
The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were scheduled in advance. Following the transactions, Mata directly holds 2,546 ADSs of Belite Bio.